Spinnovation launches biologics analysis division

Published: 8-Apr-2011
Finance Analysis Pharmaceutical

Spinnovation Biologics to provide profiling and characterisation of biologics

Spinnovation Analytical, a Dutch contract research organisation, has launched a new division called Spinnovation Biologics, which will provide spent culture media analysis and profiling and characterisation of biologics and biosimilar drugs.

Frederic Girard, chief executive of the Nijmegen-based nuclear magnetic resonance spectroscopy (NMR) specialist, said spent media analysis with Spedia-NMR would be the new company’s core service.

‘Spedia-NMR is unique and can deliver a step-fold increase in throughput and detail over standard methods, in as few as five working days,’ he said.

Spinnovation Biologics will also offer process and product bioanalysis, enabling clients to benefit from advanced insights into cell culture to enhance productivity, scalability, and reliability for QA/QC control, cGMP production and support Quality by Design.

In addition to Spedia-NMR technology, Spinnovation Biologics has a broad spectrum of analysis methods in house, including: LC-MS, LC-NMR, LC-SPE-NMR and LC-SPE-NMR-MS.

See more

You may also like

Research & Development

Pivot Park and Spinnovation Analytical join forces

Read more
To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands

Trending Articles

  1. Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
  2. The IND advantage: why early derisking is a strategic imperative for complex biologics As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
  3. Strengthening US pharmaceutical supply: SCHOTT Pharma inaugurates expanded vial production in Lebanon, PA SCHOTT Pharma has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs — from biologics and other complex injectable therapies to vaccines and emergency room medications
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
  5. Nestlé Health Science and IdB partner to bring VOWST to Europe Nestlé Health Science and IdB Holding have signed a licensing agreement to seek EMA approval for VOWST, the only FDA-approved oral live biotherapeutic for recurrent C. diff prevention

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Research & Development

Pivot Park and Spinnovation Analytical join forces

To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands
Analysis

Spinnovation Biologics predicts bioproduction performance

With the launch of Spedia-Predict
Pharmaceutical

Spinnovation introduces approach to improve biologicals manufacturing processes

Spinnovation technology delivers optimal cell viability and density, with the right safety and quality parameters in a short time frame
Analysis

Spinnovation Biologics offers service choices to meet individual analysis needs for bioprocess optimisation

Unique mix of services delivers essential support for the development and manufacture of biologics
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Subscribe now